FDA
-
-
-
-
-
-
-
Ovid Therapeutics Announces Appointment of Professor Robert S. Langer, Sc.D., as Chair of its Scientific Advisory Board
-
-
-
-
-
-
-
Ovid Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Ovid Therapeutics and University of Connecticut Enter into Strategic Research Collaboration to Accelerate the Development of Next-Generation Genetic Therapy for Angelman Syndrome
-
-
-
-
-
-
-
Ovid Therapeutics Announces Positive Topline Results from the Phase 2 ROCKET Trial of OV101 for the Treatment of Fragile X Syndrome
-
-
-
-
-
-
-
Ovid Therapeutics Announces Positive Initial Data from Ongoing ENDYMION Open-Label Extension Trial of Soticlestat in People with Rare Epilepsies
-
-
-
-
-
-
-
Ovid Therapeutics (OVID) Receives Orphan Drug Designation from EC for OV101 for Treatment of Angelman Syndrome
-
-
-
-
-
-
-
Ovid Therapeutics to Present at the American Academy of Neurology 71st Annual Meeting
-
251,648 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All